Related Experiment Video

Updated: Jun 8, 2026

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development
09:32

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context

Wen-Liang Kuo1, Jing Liu, Helena Mauceri

  • 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

Molecular Cancer Therapeutics
|September 30, 2010
PubMed

Insights

Enzastaurin, a multi-kinase inhibitor, shows promise in head and neck squamous cell carcinoma. Its efficacy is linked to cyclin D1 levels, suggesting it works best in tumors with low to moderate cyclin D1 expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Targeted small molecules, particularly multi-kinase inhibitors, are increasingly used in oncology.
  • Developing predictive biomarkers for multi-kinase inhibitors is challenging due to complex mechanisms of action.
  • Enzastaurin, a protein kinase C inhibitor, is being investigated for various cancers.

Purpose of the Study:

  • To investigate the efficacy of enzastaurin in squamous cell carcinoma of the head and neck (HNSCC).
  • To identify predictive biomarkers for enzastaurin response in HNSCC.
  • To elucidate the mechanisms underlying sensitivity and resistance to enzastaurin in HNSCC.

Main Methods:

  • In vitro studies using HNSCC cell lines (SQ-20B, CAL27) and tumor xenografts.
  • Assessment of tumor growth, proliferation, target phosphorylation, and cell cycle arrest.
  • Gene expression profiling and analysis of cyclin D1 expression and regulation.
  • Manipulation of cyclin D1 levels to assess its role in drug sensitivity.

Main Results:

  • Enzastaurin reduced tumor growth, inhibited proliferation, and induced cell cycle arrest in HNSCC models.
  • Gene expression analysis revealed significant alterations in cell cycle genes following enzastaurin treatment.
  • Sensitivity to enzastaurin varied among HNSCC cell lines and correlated significantly with baseline cyclin D1 protein expression.
  • Cyclin D1 levels could be modulated to reverse drug sensitivity or resistance.
  • Sensitive cell lines showed Akt-regulated cyclin D1 synthesis, while resistant lines had CCND1 gene amplification.

Conclusions:

  • Cyclin D1 is a critical determinant of enzastaurin efficacy in HNSCC.
  • Enzastaurin's effectiveness is dependent on the cellular signaling context, specifically cyclin D1 regulation.
  • Enzastaurin is likely to be most effective in HNSCC tumors with low to moderate, physiologically regulated cyclin D1 expression.
  • These findings highlight the importance of understanding cellular signaling for developing targeted cancer therapies.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...